Table 2.
Correlates of day +30 lymphopenia (ALC less than 500 × 106/l) excluding patients with early grade II–IV acute GVHD
| No. of patients | Median | % |
Univariate analysis
|
Multivariate analysis
|
|||||
|---|---|---|---|---|---|---|---|---|---|
| N = 106 | ALC | Lymphopenic | OR | 95% CI | P-value | OR | 95% CI | P-value | |
| Graft type | |||||||||
| Matched unrelated donor/BM | 48 | 580 | 42 | 1.5 | 0.7–3.2 | 0.3 | NA | ||
| Matched sibling donor/PB | 58 | 745 | 33 | 1.0 | NA | NA | |||
| Disease status at transplantation | |||||||||
| Active disease with circulating blasts | 31 | 470 | 55 | 1.0 | NA | ||||
| Active disease without circulating blasts | 38 | 700 | 26 | 0.3 | 0.1–0.8 | 0.02 | NA | ||
| CR | 37 | 760 | 32 | 0.4 | 0.1–1.1 | 0.06 | NA | ||
| Active disease with circulating blasts vs all other | 2.9 | 1.2–6.9 | 0.02 | 2.7 | 1.1–6.6 | 0.03 | |||
| CMV reactivation before day +30 | |||||||||
| Yes | 20 | 780 | 15 | 0.2 | 0.1–0.9 | 0.03 | 0.3 | 0.1–0.96 | 0.04 |
| No | 85 | 590 | 42 | 1.0 | NA | 1.0 | |||
| Donor/patient CMV serostatus | |||||||||
| Non-reactive/non-reactive | 10 | 890 | 30 | 1.0 | NA | NA | |||
| Reactive/non-reactive | 6 | 580 | 33 | 1.0 | NA | NA | |||
| Reactive/reactive | 48 | 735 | 29 | 1.0 | NA | NA | |||
| Non-reactive/reactive | 38 | 545 | 47 | 2.1 | 0.9–4.9 | 0.08 | NA | ||
| Number of previous chemotherapy regimens | |||||||||
| At least the median | 38 | 560 | 47 | 2.0 | 0.9–4.6 | 0.09 | NA | ||
| Less than the median | 68 | 670 | 31 | 1.0 | NA | NA | |||
| Age, years | |||||||||
| At least 55 | 56 | 570 | 45 | 2.1 | 0.9–4.7 | 0.08 | NA | ||
| Less than 55 | 50 | 705 | 28 | 1.0 | NA | NA | |||
| Patient sex | |||||||||
| Female | 42 | 680 | 36 | 0.9 | 0.4–2.1 | 0.8 | NA | ||
| Male | 64 | 630 | 37 | 1.0 | NA | NA | |||
| Donor/patient sex match | |||||||||
| M/M | 38 | 640 | 34 | 0.8 | 0.2–2.7 | 0.7 | NA | ||
| F/F | 15 | 690 | 40 | 1.0 | NA | NA | |||
| M/F | 27 | 670 | 33 | 0.7 | 0.2–2.8 | 0.7 | NA | ||
| F/M | 25 | 580 | 44 | 1.2 | 0.3–4.3 | 0.8 | NA | ||
| Karyotype risk group | |||||||||
| High | 40 | 625 | 35 | 0.8 | 0.4–1.9 | 0.7 | NA | ||
| Intermediate | 59 | 630 | 39 | 1.0 | NA | NA | |||
| Low | 4 | 705 | 25 | NA | NA | NA | |||
| Unknown | 3 | 700 | NA | NA | NA | ||||
| Dose of melphalan, mg/m2 | |||||||||
| 100 | 20 | 860 | 25 | 0.5 | 0.2–1.5 | 0.2 | NA | ||
| 140/180 | 86 | 630 | 39 | 1.0 | NA | NA | |||
| Mylotarg | |||||||||
| Yes | 10 | 750 | 40 | 1.2 | 0.3–4.4 | 0.8 | NA | ||
| No | 96 | 640 | 36 | 1.0 | NA | NA | |||
| Use of ATG in conditioninga | |||||||||
| Yes | 18 | 570 | 44 | 1.2 | 0.4–3.9 | 0.8 | NA | ||
| No | 30 | 580 | 40 | 1.0 | NA | NA | |||
| Time to ALC 500 × 106/lb | |||||||||
| Less than the median | 40 | 785 | 32 | 1.1 | 0.5–2.6 | 0.8 | NA | ||
| At least the median | 66 | 670 | 30 | 1.0 | NA | NA | |||
Abbreviations: ATG = antithymocyte globulin; CI = confidence interval; F = female; M = male; NA = not applicable; OR = odds ratio; PB = peripheral blood.
Early acute GVHD refers to acute GVHD diagnosed before post transplant day +30.
Totals are less than 106 for some variables because of missing data.
a
Among recipients of a BM graft.
b
Evaluated among patients who reached an ALC of 500 × 106/l by post transplant day +30.